$SCLX

Scilex Holding Co (SCLX): Completion of Acquisition or Disposition of Assets

Scilex Holding Co (SCLX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 2 sclx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Stock repurchase AGREEMENT This Stock Repurchase Agreement (this “ Agreement ”) is made and entered into effective as of July 18, 2026 (the “ Effective Date ”) by and among (i) Vivasor Holding Company, a Delaware corporation

Original reporting
Published Jul 22, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMergers & acquisitions
Primary signal
$SCLX
Neutral
medium confidence
Mentioned
$SCLX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SCLXNeutralMed
01

Why it matters

SCLX is repurchasing Series A-1 and A-2 preferred shares from the seller entities for an aggregate $11,999,762.28, with $999,980.97 paid on the effective date and the remainder paid in tranches through June 30, 2027. Payment can be made in cash and/or by assigning DVLT shares held by a subsidiary, with DVLT share counts determined using the Nasdaq-reported price immediately preceding each payment date.

02

Market read

Traders may focus on the tranche schedule and the DVLT share-price-dependent mechanics that can affect SCLX’s effective capital outlay and timing.

03

What to watch

Tranche payment dates (and the DVLT deemed share price on each payment date) can materially change the effective cost and timing of capital deployment, affecting valuation more than the headline $1.8583 price per share.

Relevance 7/10Novelty 7/10Timing: Effective July 18, 2026, with remaining purchase-price tranches due through June 30, 2027.

Background

The 8-K references Item 2.01 completion of acquisition/disposition of assets and includes an exhibit describing a stock repurchase agreement between Vivasor entities and Scilex.

Company-level read

Ticker impact

$SCLXNeutralMedium confidence
Context

Scilex (SCLX) 8-K discloses completion of an asset transaction tied to a stock repurchase agreement for preferred shares at $1.8583 per share.

Expected impact

Near-term volatility possible around tranche timing and any DVLT-share valuation, but direction is uncertain from the excerpt alone.

Evidence & confidence

This is a primary SEC 8-K disclosure with concrete deal mechanics (price per share, aggregate consideration, tranche schedule). However, the excerpt does not provide the market context for SCLX or DVLT, limiting directional conviction.

Market effects

Limited sector read-through; this appears company-specific capital structure and related-share consideration mechanics.

No clear regional market linkage from the excerpt.

No clear global macro or cross-border impact stated in the excerpt.

Counterpoint

Because part of the consideration is paid via DVLT share assignment, the economic impact to SCLX shareholders could be less favorable if DVLT trades down relative to the implied deemed price.

Key entities

  • Scilex Holding Company

    Subject of the SEC 8-K, disclosing completion of an asset transaction and a preferred-share repurchase agreement.

  • Vivasor Holding Company

    Seller entity in the stock repurchase agreement.

  • Vivasor, Inc.

    Subsidiary of Vivasor Holding Company and party to the agreement.

  • Datavault AI, Inc.

    DVLT shares are used as part of the purchase price payment mechanism.

Related articles

$SCLXMed

Scilex Shares Jump After Securing $100 Million Strategic Investment Proposal (SCLX)

Scilex Holding (NASDAQ:SCLX) shares rose about 7% after it said it signed a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based iHolding Group LLP. iHolding would buy ~6.7 million newly issued shares at $15.00 each. The funding would support expansion, product development, commercialization, acquisitions, and working capital; the deal is subject to closing conditions and approvals.

$SCLXMed

Scilex, Vera Therapeutics rise premarket; Strategy gains By Investing.com

U.S. stock index futures rose premarket as investors returned from a holiday. Scilex Holding gained 7% on a binding term sheet for a proposed $100M strategic investment. Vera Therapeutics rose 6% ahead of a July 7 FDA PDUFA decision for atacicept. Solaris Energy Infrastructure rose 3.9% after Wolfe Research coverage and a ~$55M acquisition. Strategy rose 3.4% after adopting a framework to selectively monetize up to $1.25B in Bitcoin holdings.

$SCLXMedAI 8/10

Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

Scilex Holding Company (Nasdaq: SCLX) said it signed a binding term sheet for iHolding Group LLP to invest $100 million by purchasing newly issued Scilex shares at $15.00 per share (~6.67 million shares). Proceeds would support growth, product development, commercialization, acquisitions, working capital, and IP. Closing depends on due diligence, definitive agreements, board and stockholder approvals, and regulatory approvals.